NESS ZIONA, Israel, May 13, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stagedermatology company focused on identifying, developing and commercializing branded and ...

Reports Q3 revenue $400k vs $5.4M last year. Mori Arkin, Executive Chairman of Sol-Gel, stated: “Sol-Gel continued to make steady progress in the third quarter as we advance our late-stage pipeline in ...

Sol-Gel Technologies secures $16 million for clinical trials, advancing SGT-610 for Gorlin syndrome and extending cash runway to 2027. Sol-Gel Technologies, Ltd. has announced a product purchase ...

NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a ...

NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a ...

(RTTNews) - Shares of Sol-Gel Technologies Ltd. (SLGL) have more than doubled over the last one month, thanks to positive data from its acne trials. Sol-Gel Technologies is a clinical-stage ...

NESS ZIONA, Israel & LAUSANNE, Switzerland--(BUSINESS WIRE)--Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world’s largest independent dermatology ...

NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with FDA approvals for EPSOLAY ® and TWYNEO ®, two ...

SLGL is trading near the top of its 52-week range and above its 200-day simple moving average. Price change The price of SLGL shares has decreased $0.10 since the market last closed. This is a 0.23% ...

The dermatology company's unique wrapping method makes it possible to combine two anti-acne drugs. Dermatology company Sol-Gel is considering an IPO in the coming months at a $200-300 million company ...

Sol-Gel Technologies Ltd. has announced positive results for a Phase II trial in the U.S. targeting mild-to-severe rosacea using a benzoyl peroxide drug product developed by Sol-Gel. Although benzoyl ...